Kiluma Biosciences is developing next-generation oncology diagnostics designed to identify biological signals associated with cancer risk and disease development earlier than conventional approaches — enabling earlier intervention, better outcomes, and more personalized care.
Pancreatic cancer remains one of the most lethal forms of cancer because diagnosis often occurs after disease has progressed beyond curative intervention. Earlier biological detection represents one of oncology's largest unmet needs.
~13%
5-year survival rate
<20%
Detected early enough for surgery
~52K
U.S. deaths each year
#3
Leading cause of cancer death by 2030 (projected)
STAGE 1
Baseline biology
STAGE 2
Subclinical signals
STAGE 3
Detectable interception window
STAGE 4
Current diagnostic threshold
Today's medicine acts at the right side of this continuum. Kiluma is engineering tools that act on the left — where intervention has the greatest potential to change outcomes.
A next-generation cancer interception platform built upon the proprietary Intercept IQ™ architecture. OncoIntercept is not a single biomarker test — it is a comprehensive disease interception platform designed to detect biological changes associated with cancer development at the molecular level, before traditional clinical signs emerge.
Fragmented tumor and tissue DNA circulating in plasma.
Regulatory states that change before structural mutations.
Tissue-of-origin and disease-specific methylation patterns.
Secreted and shed proteins reflecting tissue distress.
Systemic immune signaling associated with disease initiation.
Metabolite shifts revealing altered cellular bioenergetics.
Demographics, history, and longitudinal phenotype data.
Models that integrate signals invisible to any single assay.
The goal: move cancer detection upstream — where intervention may be more effective and outcomes potentially improved.
Pancreatic cancer often develops silently, with biological and molecular changes occurring long before symptoms appear or tumors become detectable through conventional imaging. By the time many patients are diagnosed, the disease has frequently progressed to advanced stages. Kiluma Biosciences is developing molecular diagnostic technologies designed to investigate the earliest biological indicators of pancreatic stress and disease.
Stage 01 / 06
Healthy Biology
Healthy Pancreas
Baseline pancreatic biology. Endocrine and exocrine compartments operate within normal physiological parameters.
Continuous loop · pauses on hover
Detection Window
Healthy Biology
Molecular Detection Window
Clinical Symptoms
Traditional Diagnosis
Biological changes may precede conventional clinical diagnosis. Kiluma's technology is in research and development and has not been clinically validated for cancer detection.
Stage Timeline
Healthy
Stress
Precancer
Early Tumor
Local
Advanced
Understanding molecular changes before symptoms become apparent.
Earlier diagnosis may increase the range of therapeutic strategies available, depending on disease stage.
Earlier identification may help support clinical research and patient enrollment in future studies.
Blood-based molecular biomarkers may provide additional biological insights beyond conventional imaging alone.
Kiluma Biosciences is investigating blood-based molecular diagnostics designed to evaluate potential biological indicators of pancreatic stress and disease. This technology is in research and development and has not been clinically validated. Statements above describe research goals and do not represent clinical performance claims.
A growing body of peer-reviewed research demonstrates that pancreatic disease develops through progressive molecular and cellular changes long before symptoms become apparent. Advances in cell-free DNA, tissue-specific methylation, epigenetic biomarkers, protein biomarkers, and multi-omic analysis are creating new opportunities to investigate pancreatic biology through minimally invasive blood-based testing.
The publications below provide the scientific rationale informing Kiluma's research approach. They are independent works by other investigators and do not validate Kiluma's proprietary technology.
Pisapia et al.
Reviews how chronic pancreatic injury, precancerous lesions, and tissue-specific DNA methylation changes may precede pancreatic cancer development, highlighting circulating cfDNA methylation as a promising approach for investigating early biological changes within the pancreas.
Liu et al.
Examines how circulating cfDNA methylation, liquid biopsy technologies, and integrated biomarker strategies may improve pancreatic cancer detection and monitoring — emphasizing combinations of molecular signals over any single biomarker.
Henriksen et al.
Explores how chronic inflammation, pancreatic injury, and epigenetic dysregulation contribute to pancreatic cancer development, and highlights DNA methylation as a promising biomarker for understanding early disease biology.
Berger et al.
Demonstrates how combining protein biomarkers with methylated circulating cfDNA may improve early pancreatic cancer detection, supporting a multi-analyte, multi-omic diagnostic strategy.
Cao et al.
Investigates blood-based epigenomic approaches using circulating cfDNA to evaluate early pancreatic cancer biology and reinforces the growing role of epigenetic biomarkers in minimally invasive diagnostics.
Guler et al.
Demonstrates that epigenetic 5-hydroxymethylcytosine signatures in circulating cfDNA may help distinguish early-stage pancreatic cancer, highlighting the potential of advanced epigenomic profiling.
Neiman et al.
Landmark work showing that tissue-specific methylation signatures can identify circulating beta-cell-derived DNA in blood — demonstrating how organ-specific cell death may be detected through blood-based molecular analysis.
Rather than focusing solely on detecting established disease, Kiluma Biosciences is advancing a molecular diagnostics platform designed to investigate the earliest biological indicators of pancreatic stress.
Our research is informed by growing evidence that pancreatic disease may involve progressive molecular changes — including endocrine dysfunction, exocrine dysfunction, tissue-specific cell death, epigenetic alterations, circulating cell-free DNA, protein biomarkers, and inflammatory signaling — long before conventional imaging or clinical symptoms emerge.
By integrating these biological signals through advanced molecular analysis and artificial intelligence, we aim to support the future development of earlier and more comprehensive approaches to pancreatic disease investigation.
Platform Workflow
Healthy Pancreas
Cellular Stress
Beta-Cell Biology
Epigenetic Alterations
Cell-Free DNA Release
Protein Biomarkers
Artificial Intelligence
Multi-Omic Molecular Intelligence
Earlier Biological Insight
Kiluma Biosciences is researching blood-based molecular diagnostics designed to evaluate potential biological indicators of pancreatic stress. This technology is in research and development and has not been clinically validated. Inclusion of any publication above does not imply endorsement of Kiluma's proprietary technology.
Most cancers develop over many years before diagnosis. The future of healthcare is not simply diagnosing disease earlier — it is identifying the biological processes that precede disease itself.
Traditional Healthcare
Reactive. Symptom-driven. Often too late.
The Kiluma Vision
Proactive. Biology-driven. Designed to change outcomes.
No single biomarker can fully explain disease risk. Kiluma's long-term vision is to integrate multiple biological data layers into a comprehensive disease interception model capable of identifying subtle patterns associated with cancer development. The future of diagnostics is multiomic.
Inherited and somatic variants that establish baseline risk and drive tumor biology.
Methylation and chromatin state — the earliest layer of disease reprogramming.
Functional protein output reflecting active disease processes in real time.
Small-molecule fingerprints of cellular bioenergetics and tumor microenvironment.
Cytokine and immune-cell signaling that often precedes overt malignancy.
Phenotypic context that grounds molecular signals in individualized risk.
